• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Late Breaking Abstract - Inhaled corticosteroids (ICS), blood eosinophils (EOS), and FEV1 decline in patients with Chronic Obstructive Pulmonary Disease in a large UK primary healthcare setting
Conclusions: Regardless of blood EOS level, ICS-containing medication is associated with slower rates of FEV1 decline in COPD patients.Funding: GSK study 208602
Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Whittaker, H., Mullerova, H., Jarvis, D., Barnes, N., Jones, P., Compton, C., Kiddle, S., Quint, J. Tags: Epidemiology Source Type: research

LATE-BREAKING ABSTRACT: Study to understand mortality and morbidIty in COPD (SUMMIT)
Chronic obstructive pulmonary disease (COPD) is recognized as having significant systemic manifestations associated with increased mortality and morbidity (Agusti, Proc Am Thorac Soc 2005;2:367-70), in particular cardiovascular (CV) disease. More patients with moderate COPD die from lung cancer and CV diseases than from COPD (Calverley, N Engl J Med 2007;356:775-89).Post-hoc analyses from the TORCH study suggest an inhaled corticosteroid/long acting beta2 agonist (ICS/LABA) combination may reduce mortality and CV events (e.g. acute coronary syndrome [ACS] and stroke) in patients with moderate COPD (≥50% predicted FEV1) ...
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Vestbo, J., Anderson, J., Brook, R. D., Calverley, P., Celli, B., Crim, C., Martinez, F., Yates, J., Newby, D. Tags: 1.1 Clinical Problems Source Type: research

Chronic obstructive pulmonary disease.
Abstract The global prevalence of physiologically defined chronic obstructive pulmonary disease (COPD) in adults aged >40 yr is approximately 9-10 per cent. Recently, the Indian Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis in Adults had shown that the overall prevalence of chronic bronchitis in adults >35 yr is 3.49 per cent. The development of COPD is multifactorial and the risk factors of COPD include genetic and environmental factors. Pathological changes in COPD are observed in central airways, small airways and alveolar space. The proposed pathogenesis of COPD includes pr...
Source: The Indian Journal of Medical Research - February 1, 2013 Category: Biomedical Science Authors: Vijayan VK Tags: Indian J Med Res Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news